These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19667110)

  • 1. Identification of genetic variants associated with response to statin therapy.
    Mega JL; Morrow DA; Brown A; Cannon CP; Sabatine MS
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1310-5. PubMed ID: 19667110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
    Tung P; Wiviott SD; Cannon CP; Murphy SA; McCabe CH; Gibson CM
    Am J Cardiol; 2009 Apr; 103(8):1056-60. PubMed ID: 19361589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study.
    Chiodini BD; Franzosi MG; Barlera S; Signorini S; Lewis CM; D'Orazio A; Mocarelli P; Nicolis E; Marchioli R; Tognoni G; ;
    Eur Heart J; 2007 Aug; 28(16):1977-83. PubMed ID: 17567623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
    Tavintharan S; Lim SC; Chan YH; Sum CF
    Diabetes Obes Metab; 2007 Jan; 9(1):81-6. PubMed ID: 17199722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
    Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype.
    Ilveskoski E; Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Laippala P; Karhunen PJ; Knuuti J
    Scand J Clin Lab Invest; 2007; 67(7):723-34. PubMed ID: 17852827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.
    Vaisi-Raygani A; Rahimi Z; Nomani H; Tavilani H; Pourmotabbed T
    Clin Biochem; 2007 Oct; 40(15):1150-6. PubMed ID: 17689519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
    Pedro-Botet J; Schaefer EJ; Bakker-Arkema RG; Black DM; Stein EM; Corella D; Ordovas JM
    Atherosclerosis; 2001 Sep; 158(1):183-93. PubMed ID: 11500190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
    Leiter LA; Martineau P; de Teresa E; Farsang C; Gaw A; Gensini G; Langer A;
    J Fam Pract; 2008 Oct; 57(10):661-8. PubMed ID: 18842192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
    Ray KK; Cannon CP
    Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
    Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
    J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.